Why should Indian Pharmaceutical focus on sustainable manufacturing?

Over the previous two decades, the Indian pharmaceutical sector has expanded at a CAGR of 11% in the domestic market and 16% in exports. While it is estimated that the Indian pharmaceutical sector will expand at a CAGR of 12% between 2020 and 2030, reaching US$130 billion by 2030, up from US$41.7 billion in 2020.

[box type=”success” align=”” class=”” width=””]But to achieve self-sufficiency, the industry must refocus on the next set of avenues to fuel the development engine, which is both strategic and sustainable in nature. Pharmaceutical companies need to focus on ensuring that their therapies don’t adversely impact the environment, society, and their business, thereby an approach towards sustainable manufacturing is needed.[/box]

To do so, the virtual twin is the starting point for sustainable pharmaceutical production, which leads to effective, safe, and inexpensive treatments. Manufacturers must adopt end-to-end manufacturing line optimizations to generate therapies more sustainably, as pharmaceutical manufacturing lines migrate from small batch production to produce precision medicines. Instead, sustainability needs to factor into pharmaceutical manufacturing from the start.

Manufacturers factor in environmental, social, and business sustainability requirements in the early stages of design to be able to optimise them. In order to do so, pharmaceutical companies must transition to digitalized manufacturing. They must digitalize their production since it is the only method for various stakeholders to collaborate and systematically determine concerns.

Three-tiered strategy

The right science-based tools integrate easily with digitalized manufacturing lines, to allow the iterative loop that guarantees pharmaceutical manufacturing to manufacture sustainably from the beginning.

This method, which allows corporations to make a positive impact, may lead and secure their layered influence. By making a positive influence on society first, by balancing access, affordability, and quality requirements to guarantee that all people have fair access to healthcare and drugs across global marketplaces. The functioning and integrity of medicinal goods, as well as serialisation across the production process, are among the proactive concerns.

Second on the environment, because firms can rapidly acquire sustainable raw materials, minimise waste and GHG emissions during manufacturing, and integrate more closely with the circular economy by implementing clean operations and energy-efficient supply chains.

Finally, it has a business impact by allowing pharmaceutical firms to confidently show global manufacturing compliance and integrity in a transparent and cost-effective manner that builds confidence and generates long-term income.

 Digitalization is the way to go

A virtual twin, or a digital duplicate of real-world pharmaceutical processes, products, and factories, is used to accomplish digital production from start to finish. It gives manufacturers the flexibility they need by providing science-based tools that may be used to design new medicines.

[box type=”success” align=”” class=”” width=””]These technologies follow scientific principles in biology, chemistry, physics, and engineering, making them an important enabler in a science-based industry like pharmaceuticals. The proper platform then brings together a wide range of stakeholders, such as designers, engineers, supply chain vendors, scientists, and others, with scientific data to speed up decision-making, process intelligence, and analysis. As a consequence, pharmaceutical companies will be able to communicate regulatory compliance and develop confidence with regulators and patients at unprecedented levels of openness.[/box]

The virtual twin combination has a decades-long transformational influence in the production phase of many highly demanding technical industries such as aerospace, high-tech, and transportation. It is now time for pharmaceutical firms to use best-in-class scientific tools to modernise their production lines and offer novel medicines while guaranteeing environmental, social, and behavioural sustainability.

Disclaimer: The views expressed in this article are those of the author and do not necessarily reflect the views of ET Edge Insights, its management, or its members

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top